Improved circulating tumor cell detection by a combined EpCAM and MCAM cell search enrichment approach in patients with breast cancer undergoing neoadjuvant chemotherapy

Molecular Cancer Therapeutics

Volumn 14, Issue 3, 2015, Pages 821-827

  Onstenk, Wendy ^a   Kraan, Jaco ^a   Mostert, Bianca ^a   Timmermans, Mieke M ^a   Charehbili, Ayoub ^b   Smit, Vincent T H B M ^b   Kroep, Judith R ^b   Nortier, Johan W R ^b   Van De Ven, Saskia ^b   Heijns, Joan B ^c   Kessels, Lonneke W ^d   Van Laarhoven, Hanneke W M ^e   Bos, Monique M E M ^f   Van De Velde, Cornelis J H ^b   Gratama, Jan W ^a   Sieuwerts, Anieta M ^a   Martens, John W M ^a   Foekens, John A ^a   Sleijfer, Stefan ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c AMPHIA HOSPITAL   (Netherlands)

^d DEVENTER HOSPITAL   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f REINIER DE GRAAF HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD146 ANTIGEN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPITHELIAL CELL ADHESION MOLECULE; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; ZOLEDRONIC ACID; CELL ADHESION MOLECULE; MCAM PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR-ASSOCIATED ANTIGEN GA733;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CELL COUNT; CIRCULATING TUMOR CELL; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; BLOOD; BREAST NEOPLASMS; CANCER STAGING; CLINICAL TRIAL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NEOADJUVANT THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TUMOR EMBOLISM;

ANTIGENS, CD146; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL ADHESION MOLECULES; CELL COUNT; ENDOTHELIAL CELLS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING;

EID: 84957546775     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0653     Document Type: Article

References (22)

1. Zhang L, Riethdorf S, Wu G, Wang T, Yang K, Peng G, et al. Meta-analysis of the prognostic value of circulating tumor cells in breast cancer. Clin Cancer Res 2012;18:5701-10.
2. Riethdorf S, Muller V, Zhang L, Rau T, Loibl S, Komor M, et al. Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. Clin Cancer Res 2010;16:2634-45.
3. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, et al. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 2012;13:688-95.
4. Schindlbeck C, Andergassen U, Hofmann S, Juckstock J, Jeschke U, Sommer H, et al. Comparison of circulating tumor cells (CTC) in peripheral blood and disseminated tumor cells in the bone marrow (DTC-BM) of breast cancer patients. J Cancer Res Clin Oncol 2013;139:1055-62.
5. Pierga JY, Bidard FC, Mathiot C, Brain E, Delaloge S, Giachetti S, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial. Clin Cancer Res 2008;14:7004-10.
6. Bidard FC, Mathiot C, Delaloge S, Brain E, Giachetti S, de Cremoux P, et al. Single circulating tumor cell detection and overall survival in nonmeta-static breast cancer. Ann Oncol 2010;21:729-33.
7. Bidard FC, Belin L, Delaloge S, Lerebours F, Ngo C, Reyal F, et al. Time-dependent prognostic impact of circulating tumor cells detection in non-metastaticbreast cancer: 70-month analysisofthe REMAGUS02 study. Int J Breast Cancer 2013;2013:130470.
8. Gorges TM, Tinhofer I, Drosch M, Rose L, Zollner TM, Krahn T, et al. Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. BMC Cancer 2012;12:178.
9. Mostert B, Kraan J, Bolt-de Vries J, van der Spoel P, Sieuwerts AM, Schutte M, et al. Detection of circulating tumor cells in breast cancer may improve through enrichment with anti-CD146. Breast Cancer Res Treat 2011;127: 33-41.
10. Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013;339:580-4.
11. Onstenk W, Kraan J, Charehbili A, Mostert B, Smit VTHBM, Kroep JR, et al. A combined EpCAM and MCAM circulating tumor cell (CTC) CellSearch enrichment to improve CTC capture rate in stage II/III breast cancer: A Dutch Breast Cancer Trialists' Group (BOOG) side study. ASCO Meeting Abstracts 2013;31:e22106.
12. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, et al. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009;101: 61-6.
13. Kraan J, Sleijfer S, Foekens JA, Gratama JW. Clinical value of circulating endothelial cell detection in oncology. Drug Discov Today 2012;17:710-7.
14. Charehbili A, van de Ven S, Smit VT, Meershoek-Klein Kranenbarg E, Hamdy NA, Putter H, et al. Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01). Ann Oncol 2014;25:998-1004.
15. Kraan J, Strijbos MH, Sieuwerts AM, Foekens JA, den Bakker MA, Verhoef C, et al. A new approach for rapid and reliable enumeration of circulating endothelial cells in patients. J Thromb Haemost 2012;10:931-9.
16. Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
17. Azim HA Jr., Rothe F, Aura CM, Bavington M, Maetens M, Rouas G, et al. Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial. Breast 2013;22:1060-5.
18. Zeng Q, Li W, Lu D, Wu Z, Duan H, Luo Y, et al. CD146, an epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer. Proc Natl Acad Sci U S A 2012;109:1127-32.
19. Imbert AM, Garulli C, Choquet E, Koubi M, Aurrand-Lions M, Chabannon C. CD146expression in human breast cancer cell lines induces phenotypic and functional changes observed in Epithelial to Mesenchymal Transition. PLoS ONE 2012;7:e43752.
20. Mego M, De Giorgi U, Dawood S, Wang X, Valero V, Andreopoulou E, et al. Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells. Int J Cancer 2011;129:417-23.
21. Mostert B, Kraan J, Sieuwerts AM, van der Spoel P, Bolt-de Vries J, Prager-van der Smissen WJ, et al. CD49f-based selection of circulating tumor cells (CTCs) improves detection across breast cancer subtypes. Cancer Lett 2012;319:49-55.
22. Strijbos MH, Kraan J, den Bakker MA, Lambrecht BN, Sleijfer S, Gratama JW. Cells meeting our immunophenotypic criteria of endo-thelial cells are large platelets. Cytometry B Clin Cytom 2007;72: 86-93.